3006.93.60.00/Blinded Placebo Oral Suspension for Diabetes Trial/China

Blinded Placebo Oral Suspension for Diabetes Trial from China

This is a liquid placebo suspension in measured doses, identical in taste and appearance to the active drug, used in double-blinded Phase III clinical trials for diabetes medications. It falls under HTS 3006.93.60.00 as a blinded clinical trial kit in liquid form for oral intake, per Chapter 30 Note 6(e), excluding actual medicaments.

Duty Rate — China → United States

125%

Rate breakdown

9903.88.0325%Except as provided in headings 9903.88.13, 9903.88.18, 9903.88.33, 9903.88.34, 9903.88.35, 9903.88.36, 9903.88.37, 9903.88.38, 9903.88.40, 9903.88.41, 9903.88.43, 9903.88.45, 9903.88.46, 9903.88.48, 9903.88.56, 9903.88.64, 9903.88.66, 9903.88.67, 9903.88.68, or 9903.88.69, articles the product of China, as provided for in U.S. note 20(e) to this subchapter and as provided for in the subheadings enumerated in U.S. note 20(f)

9903.04.60100%Pharmaceuticals Annex IV: patented pharma articles — 100% floor rate

9903.05.860%Universal product exemption (U.S. note 52(b))

9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)

Calculate with your customs value Verify classification with AI

Import Tips

• Obtain FDA approval via Investigational New Drug (IND) application confirming recognized clinical trial status to justify 3006 classification

• Provide sponsor documentation showing product is a placebo or blinded kit in measured doses for oral intake, avoiding misclassification as food under Chapter 21

• Label clearly as 'Clinical Trial Material - Not for Sale' with stability data to prevent customs holds on shelf-life concerns